Replies to post #187961 on Biotech Values

[mcbio]

REGN/AAVL

>> RTH258

Clearly a long-term threat to Eyelea here. Better efficacy (if only marginally) plus less frequent administration makes for a clearly superior drug.

I sold my REGN based on this news. Might be a year or more early, but who knows.

Do these results cause REGN to be even more dependent on AAVL's drug and increase the chance that REGN could ultimately buy AAVL out?